Group 1 - The company, Jinling Pharmaceutical, stated on November 26 that it will fulfill its information disclosure obligations in accordance with the law [2]

证券日报网讯金陵药业11月26日在互动平台回答投资者提问时表示，公司严格遵守法律法规及监管要 求，依法合规使用和管理募集资金，根据募集资金使用进度及时履行信息披露义务。 （文章来源：证券日报） ...

证券日报网讯金陵药业（000919）11月17日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东人数为33417户。 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-075 金陵药业股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次会议没有出现否决议案的情形。 2、本次会议没有涉及变更前次股东大会决议的情形。 一、会议召开和出席的情况 1、会议召开的情况 （1）召开时间 现场会议召开时间：2025 年 11 月 13 日 14:30 网络投票时间：通过深圳证券交易所系统进行网络投票的具体时 间为2025年11月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为2025年11月13日 9:15至15:00的任意时间。 （2）现场会议召开地点：南京市中央路 238 号公司本部六楼会 议室 （3）召开方式：采取现场投票与网络投票相结合的方式 （4）召 集 人：公司董事会 （5）现场会议主持人：董事长陈胜先生 （6）本次股东大会的召集与召开程序、出席会议人员资格及表 决程序，符合《公司法》《深圳证券交易所股票上市规则》等法律、 ...

江苏泰和律师事务所 关于金陵药业股份有限公司 2025 年第三次临时股东大会的 法律意见书 泰和津师事务所 JC MASTER LAW OFFICES 中国 · 南京 · 清江南路70号国家水资源大厦9层 电话: 025 84503333 传真: 025 84505533 网址: http: //www.jcmaster.com 法律意见书 江苏泰和律师事务所 关于金陵药业股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：金陵药业股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称"《公 司法》"）、中国证券监督管理委员会《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规、规范性文件和《金陵药业股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，江苏泰和律师事务所（以下简称"本所"） 接受金陵药业股份有限公司（以下简称"公司"）的委托，指派律师（以下称"本 所律师"）出席公司 2025 年第三次临时股东大会（以下简称"本次股东大会" "会议"），并出具本法律意见书。 本所律师根据《股东会规则》第六条的要求，出席了本次股东大会并按照律 师行业公认的业 ...

Core Insights - The high-pressure oxygen chamber concept has seen a decline of 0.21%, ranking among the top declines in concept sectors as of the market close on November 13 [1] - Within the sector, companies like Innovation Medical and International Medicine experienced significant declines, while six stocks saw price increases, with Dahu Co., Aoyang Health, and Samsung Medical leading the gains [1] Market Performance - The top-performing concept sectors today include: - Fluorochemical concept: +4.50% - Organic silicon concept: +4.47% - Sodium-ion battery: +4.47% - Lead metal: +4.27% - Phosphorus chemical: +4.25% [2] - The high-pressure oxygen chamber sector experienced a net outflow of 149 million yuan, with eight stocks seeing net outflows [2] Fund Flow Analysis - The stocks with the highest net outflows in the high-pressure oxygen chamber sector include: - Samsung Medical: -60.80 million yuan - Innovation Medical: -57.39 million yuan - International Medicine: -12.53 million yuan [2] - Conversely, the stocks with the highest net inflows include: - Yingkang Life: +10.12 million yuan - Hangyang Co.: +9.74 million yuan [2] Stock Performance - Key stock performances in the high-pressure oxygen chamber sector: - Samsung Medical: +0.37%, turnover rate: 2.18% - Innovation Medical: -2.00%, turnover rate: 13.41% - International Medicine: -0.80%, turnover rate: 1.13% [2]

Core Viewpoint - Jinling Pharmaceutical stated on November 12 that it will disclose information in accordance with the law, and investors should refer to the company's published announcements and periodic reports for relevant information [2] Summary by Category - **Company Information Disclosure** - The company will comply with legal requirements for information disclosure [2] - Investors are advised to check the company's announcements and periodic reports for detailed information [2]

Core Viewpoint - Jinling Pharmaceutical reported that as of November 10, 2025, the number of shareholders reached 33,417 [2] Company Summary - Jinling Pharmaceutical's shareholder count is projected to be 33,417 by November 10, 2025 [2]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its quarterly report [2][21][42] - The third-quarter financial report has not been audited [3][10][11] - The company has made retrospective adjustments to its financial data due to a merger under common control [42][43][45] Financial Data - The company has undergone a retrospective adjustment of financial data due to the acquisition of additional shares in a medical investment fund, increasing its stake from 33.33% to 78.46% [42][43] - The adjustments will reflect in the consolidated profit and cash flow statements for the previous year [44] Shareholder Information - The company will hold its third extraordinary general meeting on November 13, 2025, with provisions for both on-site and online voting [50][51][52] - The meeting will address several proposals, including amendments to the company's articles of association and rules for shareholder meetings [27][29][30] Board and Supervisory Committee Actions - The board and supervisory committee have approved the retrospective adjustment of financial data and the third-quarter report [14][16][34][36] - The board has also approved the signing of a technology transfer contract [30]

Group 1 - The company signed a technology transfer contract with Nanjing Gulou Hospital for the transfer of technical secrets related to NK cell-specific antigens and tumor-specific antigen cell connectors, with a total contract amount of 78.5 million yuan (including tax) [6][10] - The payment structure includes an upfront fee of 1.5 million yuan, progress rewards totaling 2.5 million yuan, and sales sharing up to 74.5 million yuan based on future sales [10][11] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per relevant regulations [6][7] Group 2 - The technology involved aims to enhance the targeting ability of NK cells against tumors without the need for transfection, which is a significant advancement in biomedicine [9] - The contract allows the company to develop, produce, and sell products based on the transferred technology globally and indefinitely [13] - The company anticipates that this transaction will help expand its pipeline in the biopharmaceutical sector, aligning with its long-term strategic goals [17] Group 3 - The company held a board meeting on October 24, 2025, where it approved the signing of the technology transfer contract [6][20] - The company plans to revise its articles of association and related meeting rules, including the cancellation of the supervisory board, which will be replaced by the audit committee of the board [20][21] - The proposed changes to the articles of association and meeting rules will be submitted for approval at the upcoming third extraordinary general meeting of shareholders [20]